Pioglitazone and Empagliflozin for Fatty Liver Disease in Type 2 Diabetes

A phase 4 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 120 participants.

Also called NCT06989723

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 120 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT06989723
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
South Korea (from the registry)
Registry status
  • Recruiting (from the registry)

Technical summary

Registry record NCT06989723. Randomized; double masking; primary purpose treatment. Start 2025-01-01 (actual); primary completion 2026-12-31 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Pioglitazone and Empagliflozin for Fatty Liver Disease in Type 2 Diabetes
Condition
Fatty Liver
Intervention (Drug)
Pioglitazone 15 MG [Actos]
Intervention (Drug)
Empagliflozin 10 MG [Jardiance]
Intervention (Drug)
Empagliflozin 10 MG [Jardiance] + Pioglitazone 15 MG [Actos]
Lead sponsor
Seoul National University Bundang Hospital (class: other)
Collaborator
Celltrion (class: industry)

Record details

Record id
cardio:ct-nct06989723
Content hash
5aa4aeb0b36e06735329a586e7649eda37614f6e19337d1d5c257b2bd2e6eceb